Home » News » Drug Sponsors » Allergan, Kythera amend acquisition

Allergan, Kythera amend acquisition

Thursday, August 6, 2015

Allergan and Kythera Biopharmaceuticals have amended and restated their merger agreement. Allergan’s pending acquisition of Kythera now will be an all-cash consideration.

The structure of their previously announced transaction was for $75 per share to be paid to Kythera stockholders in an 80% cash and 20% stock transaction. The other terms of the amended and restated agreement are substantially similar to those in the original agreement.

Allergan and Kythera anticipate that the all-cash transaction provided for under the amended and restated agreement can be completed more quickly than the cash and stock transaction provided for under the terms of the original agreement.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!